BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

879 related articles for article (PubMed ID: 33283409)

  • 1. The epidermal growth factor receptor variant type III mutation frequently found in gliomas induces astrogenesis in human cerebral organoids.
    Kim HM; Lee SH; Lim J; Yoo J; Hwang DY
    Cell Prolif; 2021 Feb; 54(2):e12965. PubMed ID: 33283409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
    Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
    Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.
    Mukherjee B; McEllin B; Camacho CV; Tomimatsu N; Sirasanagandala S; Nannepaga S; Hatanpaa KJ; Mickey B; Madden C; Maher E; Boothman DA; Furnari F; Cavenee WK; Bachoo RM; Burma S
    Cancer Res; 2009 May; 69(10):4252-9. PubMed ID: 19435898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma.
    Blomquist MR; Eghlimi R; Beniwal A; Grief D; Nascari DG; Inge L; Sereduk CP; Tuncali S; Roos A; Inforzato H; Sharma R; Pirrotte P; Mehta S; Fortin Ensign SP; Loftus JC; Tran NL
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.
    Figueroa JM; Skog J; Akers J; Li H; Komotar R; Jensen R; Ringel F; Yang I; Kalkanis S; Thompson R; LoGuidice L; Berghoff E; Parsa A; Liau L; Curry W; Cahill D; Bettegowda C; Lang FF; Chiocca EA; Henson J; Kim R; Breakefield X; Chen C; Messer K; Hochberg F; Carter BS
    Neuro Oncol; 2017 Oct; 19(11):1494-1502. PubMed ID: 28453784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential.
    Stockhausen MT; Kristoffersen K; Stobbe L; Poulsen HS
    Cancer Biol Ther; 2014 Feb; 15(2):216-24. PubMed ID: 24525857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
    Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
    Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
    J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
    Vaidya KS; Mitten MJ; Zelaya-Lazo AL; Oleksijew A; Alvey C; Falls HD; Mishra S; Palma J; Ansell P; Phillips AC; Reilly EB; Anderson M; Boghaert ER
    J Neurooncol; 2021 Apr; 152(2):233-243. PubMed ID: 33517558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.
    Gilder AS; Jones KA; Hu J; Wang L; Chen CC; Carter BS; Gonias SL
    J Biol Chem; 2015 Jun; 290(24):14798-809. PubMed ID: 25837250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
    Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
    Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.
    Jones KA; Gilder AS; Lam MS; Du N; Banki MA; Merati A; Pizzo DP; VandenBerg SR; Gonias SL
    Neuro Oncol; 2016 May; 18(5):667-78. PubMed ID: 26420897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells.
    Estrada-Bernal A; Lawler SE; Nowicki MO; Ray Chaudhury A; Van Brocklyn JR
    J Neurooncol; 2011 May; 102(3):353-66. PubMed ID: 20938717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma.
    Katanasaka Y; Kodera Y; Kitamura Y; Morimoto T; Tamura T; Koizumi F
    Mol Cancer; 2013 Apr; 12():31. PubMed ID: 23617883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FHL2 interacts with EGFR to promote glioblastoma growth.
    Sun L; Yu S; Xu H; Zheng Y; Lin J; Wu M; Wang J; Wang A; Lan Q; Furnari F; Cavenee W; Purow B; Li M
    Oncogene; 2018 Mar; 37(10):1386-1398. PubMed ID: 29321665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
    Hu L; Shen D; Liang D; Shi J; Song C; Jiang K; Menglin Ren ; Du S; Cheng W; Ma J; Li S; Bi X; Barr MP; Fang Z; Xu Q; Li W; Piao H; Meng S
    Cancer Lett; 2020 Nov; 493():156-166. PubMed ID: 32860853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.